Showing 5501-5510 of 10175 results for "".
- Secukinumab Reduces Erosions in Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/secukinumab-reduces-erosions-in-psoriatic-arthritis-patients/2471713/Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial. The study evaluated the impact of the I
- Adverse Event Reporting in Dermatology RCTs Falls Short of CONSORT Harms Guidelines: Analysishttps://practicaldermatology.com/news/adverse-event-reporting-in-dermatology-rcts-falls-short-of-consort-harms-guidelines-analysis/2471683/A new review assessing adverse event (AE) reporting in dermatology randomized controlled trials (RCTs) has significant gaps in adherence to the Consolidated Standards of Reporting Trials (CONSORT) Harms guidelines. The systemat
- Meta-Analysis Validates SLNB Prediction Toolshttps://practicaldermatology.com/news/meta-analysis-validates-slnb-prediction-tools/2471653/A new systematic review and meta-analysis found several externally validated risk prediction models for sentinel lymph node biopsy (SLNB) positivity in melanoma with strong discriminative performance, though significant heterogeneity was observed.
- Bempikibart Shows Durable Responses, Post-Dosing Cessation for Severe AAhttps://practicaldermatology.com/news/Bempikibart-Shows-Durable-Responses-Post-Dosing-Cessation-Severe-AA/2471651/A novel IL-7/TSLP bifunctional receptor agonist has shown long-term durable responses and post-dosing cessation for patients with severe or very severe alopecia areata, according to a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, by Brett King,
- PN Therapeutic Pipeline Continues to Show Promisehttps://practicaldermatology.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der
- Treating Hyperpigmented/Hypertrophic Scars with Microneedling in Skin of Colorhttps://practicaldermatology.com/news/Treating-Hyperpigmented-Hypertrophic-Scars-Microneedling-Skin-Color/2471641/Robyn Siperstein, MD, FAAD, presented “Use of Microneedling in Skin of Color: Treating Hyperpigmented and Hypertrophic Scars” at the 2025 American Academy of Dermatology Annual Meeting Sunday. “The key to this treatment and how I’ve really changed my anti-aging treatments are two things: O
- Upadacitinib Shows Superior Skin Clearance in Head and Neck Atopic Dermatitis Compared to Dupilumabhttps://practicaldermatology.com/news/Upadacitinib-Shows-Superior-Skin-Clearance-Head-Neck-Atopic-Dermatitis-Compared-Dupilumab/2471639/A numerically higher proportion of patients receiving upadacitinib achieved Eczema Area and Severity Index (EASI) 75/90/100 in the head and neck as early as 2 weeks after treatment was initiated compared with those receiving dupilumab in new Level Up study data present
- New Revenue Cycle Management Service Unveiledhttps://practicaldermatology.com/news/New-Revenue-Cycle-Management-Service-Unveiled/2471638/A new solution to alleviate the challenges posed by insurance claim denials and make it easier for providers to salvage denied claims and increase their reimbursement was on display at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, as Nextech previewed the late
- Analysis: Strontium Cream Reduces Pruritus in Hidradenitis Suppurativa Patientshttps://practicaldermatology.com/news/analysis-strontium-cream-reduces-pruritus-in-hidradenitis-suppurativa-patients/2471630/Topical strontium cream significantly alleviates pruritus in patients with hidradenitis suppurativa (HS), according to a recent study published in the Journal of Clinical and Aesthetic Dermatology.
- Remibrutinib Shows Positive Effects on Sleep, Daily Activities for CSU Patientshttps://practicaldermatology.com/news/Remibrutinib-Shows-Positive-Effects-Sleep-Daily-Activities-CSU-Patients/2471637/Remibrutinib’s impact on sleep deprivation and daily activities for patients with chronic spontaneous urticaria (CSU) were highlighted in a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Robert Snyder, MD, FAAD, presented “Effect of Remib